Chemistry:CPM-LAD

From HandWiki

CPM-LAD, or CYPM-LAD, also known as 6-(cyclopropylmethyl)-6-nor-LSD, is a serotonin receptor modulator and putative psychedelic drug of the lysergamide family.[1][2][3][4] It is the analogue of LSD in which the methyl group at the 6 position has been replaced with a cyclopropylmethyl group.[1][2][3]

Use and effects

Unlike related lysergamides, CPM-LAD was not mentioned in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved) and is not known to have been tested in humans.[5]

Interactions

Pharmacology

Pharmacodynamics

CPM-LAD showed affinity (Ki) values for serotonin receptors of 10.9 nM for serotonin-labeled 5-HT1 receptors and 7.7 nM for ketanserin-labeled 5-HT2 receptors.[1][2] These affinities were very similar to but slightly lower than those of LSD.[1][2] CPM-LAD fully substituted for LSD in rodent drug discrimination tests with an ED50 of 0.067 μmol/kg, relative to a dose of 0.046 μmol/kg in the case of LSD (with CPM-LAD about 1.5-fold less potent than LSD).[1][2] Additional pharmacology for CPM-LAD has also been published.[4]

History

CPM-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University in 1987.[3] Subsequently, it was patented by Gilgamesh Pharmaceuticals in 2022, who further studied and described its pharmacology.[4] Derivatives of CPM-LAD have also been patented by Daniel Trachsel and Matthias Liechti and colleagues in association with MindMed.[6]

Society and culture

Canada

CPM-LAD is not a controlled substance in Canada as of 2025.[7]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "Lysergamides revisited". NIDA Research Monograph 146: 52–73. 1994. PMID 8742794. https://archives.nida.nih.gov/sites/default/files/monograph146.pdf#page=57. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "Stereochemical Aspects of Hallucinogenesis". Biochemistry and Physiology of Substance Abuse. 3. Boca Raton, Fla.: CRC Press. 1991. pp. 1–39. ISBN 978-0-8493-4463-3. OCLC 26748320. https://bitnest.netfirms.com/external/Books/BiochemistryPhysiologySubstanceAbuse3.1. "TABLE 1 Effects of N-(6)-Alkyl Subtituents on LSD-Like Behavior and Serotonin Receptor Affinity in Rats [...]" 
  3. ↑ 3.0 3.1 3.2 Hoffman AJ (1987). Synthesis and pharmacological evaluation of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives (Ph.D. thesis). Purdue University. . Retrieved 30 June 2025.
  4. ↑ 4.0 4.1 4.2 Kruegel AC, "Novel ergolines and methods of treating mood disorders", WO patent 2022226408A1, published 25 April 2022 Example 13: Preparation of (6aR,9R)-N,N-diethyl-7-(cyclopropylmethyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (13) [...]
  5. ↑ Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. http://www.erowid.org/library/books_online/tihkal/tihkal.shtml. 
  6. ↑ Trachsel D, Liechti ME, Lustenberger F, "Lysergic acid derivatives with modified LSD-like action", US patent 2023/0414583, published 28 December 2023
  7. ↑ "Controlled Drugs and Substances Act". https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CPM-LAD&oldid=4247001"